培美曲塞单药维持治疗晚期非小细胞肺腺癌的临床疗效分析

Clinical Efficacy of Pemetrexed Monotherapy in the Treatment of Advanced Non-small Cell Lung Adenocarcinoma

目的探讨培美曲塞单药治疗晚期非小细胞肺腺癌的临床疗效分析。方法随机选择2015年1月—2017年1月该院内科收治的100例晚期非小细胞肺腺癌患者作为研究对象,所有患者在一线治疗中均选择吉西他滨联合顺铂方案化疗获得疾病控制,并在后续治疗中使用培美曲塞单药或多西他赛治疗,按照治疗方法不同分成两组,每组50例,对照组采用多西他赛75 mg/m^2治疗,观察组采用培美曲塞500 mg/m^2进行治疗,观察两组治疗效果。结果两组患者均顺利完成计划治疗,观察组完全缓解7例,部分缓解18例,稳定18例,恶化7例,对照组完全缓解1例,部分缓解19例,稳定18例,恶化12例,两组治疗总有效率相近差异无统计学意义(P>0.05);观察组患者治疗过程中恶心呕吐、感觉神经异常、肝功能损害等不良反应发生率明显低于对照组,两组比较差异有统计学意义(P<0.05);而白细胞下降和肾功能损害等发生情况与对照组比较差异无统计学意义(P>0.05)。结论培美曲塞单药治疗治疗晚期非小细胞肺腺癌毒副反应较少,是一种安全有效的治疗方案。

Objective This paper tries to investigate the clinical efficacy of pemetrexed monotherapy in the treatment of advanced non-small cell lung cancer. Methods 100 patients with advanced non-small-cell lung adenocarcinoma treated in the department from January 2015 to January 2017 were random selected as the study subjects. All patients were treated with gemcitabine plus cisplatin chemotherapy for first-line treatment and were followed up for disease control. Treatments were treated with pemetrexed alone or docetaxel, divided into two groups according to different treatment methods. Each group consisted of 50 patients. The control group received docetaxel 75 mg/m^2 and the observation group received pemetrexed 500 mg/m^2 treatment, observe the treatment effect of the two groups. Results The two groups of patients completed the planned treatment successfully. In the observation group, 7 cases were completely relieved, 18 cases were partially relieved, 18 cases were stable, and 7 cases deteriorated. The control group completely resolved 1 case, partially relieved 19 cases, stabilized 18 cases, and worsened 12 cases. The total effective rate of treatment in the group was similar,the difference without statistical significance（P〉0.05）. The incidence of adverse reactions such as nausea and vomiting, sensory nerve abnormalities, and liver function impairment in the observation group was significantly lower than that in the control group. There was a significant difference between the two groups. the difference was Statistical significance（P〈0.05）; There was no statistically significant difference between the occurrence of leukopenia and renal impairment compared with the control group the difference was not statistically significant（P〉0.05）. Conclusion Pemetrexed monotherapy for the treatment of advanced non-small cell lung adenocarcinoma has fewer side effects and is a safe and effective treatment.